Coya Therapeutics Presents Updated ALS Biomarker Data at the 2nd Annual Johnson Center Symposium
Business Wire
HOUSTON--(BUSINESS WIRE)--Coya Therapeutics, Inc. (Nasdaq: COYA) (“Coya” or the “Company”), a clinical-stage biotechnology..
HOUSTON--(BUSINESS WIRE)--Coya Therapeutics, Inc. (Nasdaq: COYA) (“Coya” or the “Company”), a clinical-stage biotechnology..
HOUSTON--(BUSINESS WIRE)--Coya Therapeutics, Inc. (“Coya” or the “Company”), a clinical-stage biotechnology company..
· Revenues excluding Covid test sales increased 10.3% for the second fiscal quarter of 2024 vs the second fiscal quarter of..